<DOC>
	<DOCNO>NCT00020046</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide may stop growth prostate cancer stop blood flow tumor . PURPOSE : Randomized phase II trial compare effectiveness docetaxel without thalidomide treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Docetaxel With Without Thalidomide Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy thalidomide docetaxel term clinical response patient androgen-independent metastatic prostate cancer . II . Compare pharmacokinetics docetaxel without thalidomide patient III . Determine whether pharmacodynamic relationship exist plasma concentration clinical activity toxicity regimens patient population . IV . Compare change molecular marker angiogenesis marker apoptosis treatment regimens patient . PROTOCOL OUTLINE : This randomize study . Patients randomize one two treatment arm . Arm I : Patients receive docetaxel IV 30 minute weekly 3 week . Arm II : Patients receive oral thalidomide daily begin day 2 docetaxel IV 30 minute day 2 , 9 , 16 . Treatment continue every 28 day arm absence unacceptable toxicity disease progression . Patients follow every 2 month . PROJECTED ACCRUAL : A total 75 patient ( 25 arm I 50 arm II ) accrue study within 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm androgenindependent metastatic adenocarcinoma prostate Clinically progressive disease document least 1 follow : Two consecutively rise PSA level ( PSA least 5.0 ) At least 1 new lesion bone scan Progressive measurable disease If prior surgical castration , serum testosterone must less 50 ng/mL continue gonadotropinreleasing hormone If receive antiandrogen PSA level rising , must demonstrate continued rise PSA 4 week stop flutamide 6 week stop bicalutamide nilutamide No brain metastasis Prior/Concurrent Therapy Biologic therapy : No prior thalidomide Chemotherapy : No prior chemotherapy metastatic prostate cancer No prior docetaxel Endocrine therapy : See Disease Characteristics Radiotherapy : Recovered prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Patient Characteristics Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.0 mg/dL AST/ALT le 2.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 40 mL/min Cardiovascular : No history myocardial infarction within past 6 month No uncontrolled congestive heart failure angina pectoris Other : No prior active malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ bladder Fertile patient must use effective contraception least 1 month prior , , 1 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>cellular diagnosis , prostate cancer</keyword>
	<keyword>genetic condition</keyword>
	<keyword>male reproductive cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>stage , prostate cancer</keyword>
</DOC>